CREBBP IS A MAJOR PROGNOSTIC BIOMARKER FOR RELAPSE IN CHILDHOOD B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: A NATIONAL STUDY OF UNSELECTED COHORT
Krstevska Bozhinovikj E1, Matevska-Geshkovska N1, Staninova Stojovska M1,
Gjorgievska E1, Jovanovska A2, Kocheva S2*, Dimovski A1,3*
*Corresponding Author: *Corresponding Authors: Prof. Aleksandar Dimovski MD PhD. Center for Biomolecular Pharmaceutical
Analyses, Faculty of Pharmacy, University Ss. Cyril and Methodius in Skopje, Mother Theresa 47, 1000
Skopje, N. Macedonia adimovski@ff.ukim.edu.mk; phone number: +38923119694 ext109;
Research Center for Genetic Engineering and Biotechnology “Georgi D. Efremov”, Macedonian Academy
of Sciences and Arts, Bul. Krste Misirkov 2, 1000, Skopje, N. Macedonia, a.dimovski@manu.edu.mk;
phone number: +38923235411
page: 5
|
|
REFERENCES
1.
Childhood Acute Lymphoblastic Leukemia Treatment
(PDQ®) - NCI. Available online: https://www.cancer.
gov/types/leukemia/hp/child-all-treatment-pdq (ac-
cessed on 16.10.2024).
2.
SEER*Explorer Application. Available online:
https://seer.cancer.gov/statistics-network/explorer/
application.html?site=92&data_type=1&graph_
type=1&compareBy=sex&chk_sex_1=1&rate_
type=2&race=1&age_range=16&advopt_
precision=1&advopt_show_ci=on&hdn_
view=0&advopt_show_apc=on&advopt_
display=2#resultsRegion0 (accessed on 16.10.2024)
3.
Forero RM, Hernández M, Hernández-Rivas JM.
Genetics of Acute Lymphoblastic Leukemia. In Leu-
kemia. Prof. Margarita Guenova (Ed.); IntechOpen:
London, UK, 2013; doi:10.5772/55504
4.
Studd JB, Cornish AJ, Hoang PH, Law P, Kinnersley
B, Houlston R. Cancer drivers and clonal dynamics
in acute lymphoblastic leukaemia subtypes. Blood
Cancer J. 2021;11(11):1-10. doi:10.1038/s41408-
021-00570-9
5.
Mullighan CG. The molecular genetic makeup
of acute lymphoblastic leukemia. Hematology.
2012;2012(1):389-396. doi:10.1182/asheducation.
V2012.1.389.3798360
6.
Hunger SP, Mullighan CG. Redefining ALL classifica-
tion: toward detecting high-risk ALL and implement-
ing precision medicine. Blood. 2015;125(26):3977-
3987. doi:10.1182/blood-2015-02-580043
7.
Woo JS, Alberti MO, Tirado CA. Childhood B-acute
lymphoblastic leukemia: a genetic update. Exp. hema-
tol. oncol. 2014;3(1):16. doi:10.1186/2162-3619-3-16
8.
Inaba H, Greaves M, Mullighan CG. Acute lympho-
blastic leukaemia. The Lancet. 2013;381(9881):1943-
1955. doi:10.1016/S0140-6736(12)62187-4
9.
Rob Pieters, Charles G. Mullighan, Stephen P. Hun-
ger. Advancing Diagnostics and Therapy to Reach
Universal Cure in Childhood ALL. J. Clin. Oncol.
2023;41:5579-5591. doi:10.1200/JCO.23.01286
10. Chang TC, Chen W, Qu C, et al. Genomic Determi-
nants of Outcome in Acute Lymphoblastic Leukemia.
J. Clin. Oncol. 2024;42(29):3491-3503. doi:10.1200/
JCO.23.02238
11. Brady SW, Roberts KG, Gu Z, et al. The genomic
landscape of pediatric acute lymphoblastic leuke-
mia. Nat Genet. 2022;54(9):1376-1389. doi:10.1038/
s41588-022-01159-z
12. Morscio J, Van Vlierberghe P. Chemotherapy at
the wheel of ALL relapse. Blood. 2020;135(1):4-5.
doi:10.1182/blood.2019003870
13. Mullighan CG, Phillips LA, Su X, et al. Genomic
Anal-
ysis of the Clonal Origins of Relapsed Acute Lympho-
blastic Leukemia. Science. 2008;322(5906):1377-
1380. doi:10.1126/science.1164266
14. Zhang H, Wang H, Qian X, et al. Genetic mutational
analysis of pediatric acute lymphoblastic leukemia
from a single center in China using exon sequencing.
BMC Cancer. 2020;20(1):211. doi:10.1186/s12885-
020-6709-7
15. Ueno H, Yoshida K, Shiozawa Y, et al. Landscape of
driver mutations and their clinical impacts in pedi-
atric B-cell precursor acute lymphoblastic leukemia.
Blood Adv. 2020;4(20):5165. doi:10.1182/bloodad-
vances.2019001307
16. van Dongen JJM, Langerak AW, Brüggemann M,
et al. Design and standardization of PCR primers
and protocols for detection of clonal immunoglobu-
lin and T-cell receptor gene recombinations in sus-
pect lymphoproliferations: report of the BIOMED-2
Concerted Action BMH4-CT98-3936. Leukemia.
2003;17(12):2257-2317. doi:10.1038/sj.leu.2403202
17. Krstevska Bozhinovikj E, Matevska-Geshkovska
N, Stojovska M, et al. Presence of Minimal Re-
sidual Disease Determined by Next-Generation Se-
quencing Is Not a Reliable Prognostic Biomarker
in Children with Acute Lymphoblastic Leukemia.
Leuk Lymphoma 2024 (submitted) doi:10.22541/
au.172536128.83797266/v1
18. van Dongen JJ, Macintyre EA, Gabert JA, et al. Stan-
dardized RT-PCR analysis of fusion gene transcripts
from chromosome aberrations in acute leukemia for
detection of minimal residual disease. Report of the
BIOMED-1 Concerted Action: investigation of mini-
mal residual disease in acute leukemia. Leukemia.
1999;13(12):1901-1928. doi:10.1038/sj.leu.2401592
19. ALL IC-BFM 2009 A randomized trial of the I-BFM-
SG for the management of childhood non-B acute
lymphoblastic leukemia; Available online: https://
ascopubs.org/doi/suppl/10.1200/JCO.22.01760/
suppl_file/protocol1_jco.22.01760.pdf (accessed
16.10.2024)
20. Stanulla M, Dagdan E, Zaliova M, et al. IKZF1p-
lus Defines a New Minimal Residual Disease–De-
pendent Very-Poor Prognostic Profile in Pediatric
B-Cell Precursor Acute Lymphoblastic Leukemia.
J. Clin. Oncol. 2018;36(12):1240-1249. doi:10.1200/
JCO.2017.74.3617
21. Pui CH, Mullighan CG, Evans WE, Relling MV. Pediat-
ric acute lymphoblastic leukemia: where are we going
and how do we get there? Blood. 2012;120(6):1165-
1174. doi:10.1182/blood-2012-05-378943
22. Li B, Brady SW, Ma X, et al. Therapy-induced muta-
tions drive the genomic landscape of relapsed acute
lymphoblastic leukemia. Blood. 2020;135(1):41-55.
doi:10.1182/blood.2019002220
23. Oshima K, Khiabanian H, da Silva-Almeida AC,
et al. Mutational landscape, clonal evolution pat-
terns, and role of RAS mutations in relapsed acute
lymphoblastic leukemia. Proc Natl Acad Sci U
S A. 2016;113(40):11306-11311. doi:10.1073/
pnas.1608420113
24. Sayyab S, Lundmark A, Larsson M, et al. Mutational
patterns and clonal evolution from diagnosis to re-
lapse in pediatric acute lymphoblastic leukemia. Sci
Rep. 2021;11(1):15988. doi:10.1038/s41598-021-
95109-0
25. Malinowska-Ozdowy K, Frech C, Schönegger A,
et al. KRAS and CREBBP mutations: a relapse-
linked malicious liaison in childhood high hyper-
diploid acute lymphoblastic leukemia. Leukemia.
2015;29(8):1656-1667. doi:10.1038/leu.2015.107
26. Zhu Y, Wang Z, Li Y, et al. The Role of CREBBP/
EP300 and Its Therapeutic Implications in Hema-
tological Malignancies. Cancers. 2023;15(4):1219.
doi:10.3390/cancers15041219
27. Ramírez-Komo JA, Delaney MA, Straign D, et al.
Spontaneous loss of B lineage transcription factors
leads to pre-B leukemia in Ebf1+/–Bcl-xLTg mice.
Oncogenesis. 2017;6(7):e355-e355. doi:10.1038/
oncsis.2017.55
28. Yang JJ, Bhojwani D, Yang W, et al. Genome-wide
copy number profiling reveals molecular evolution
from diagnosis to relapse in childhood acute lympho-
blastic leukemia. Blood. 2008;112(10):4178-4183.
doi:10.1182/blood-2008-06-165027
29. Li X, Lin S, Liao N, et al. The RAS-signaling-
pathway-mutation-related prognosis in B-cell
acute lymphoblastic leukemia: A report from South
China children’s leukemia group. Hematol. Oncol.
2024;42(3):e3265. doi:10.1002/hon.3265
30. Park KJ, Kim IS. Clinically actionable mutations
identified in Korean patients with high-risk acute lym-
phoblastic leukemia. Ann Oncol. 2018;29:viii370-
viii371. doi:10.1093/annonc/mdy286.036
31. Vervoort BMT, Butler M, Grünewald KJT, et al.
IKZF1 gene deletions drive resistance to cytarabine
in B-cell precursor acute lymphoblastic leukemia.
Haematologica. Published online June 6, 2024.
doi:10.3324/haematol.2023.284357
32. Stanulla M, Cavé H, Moorman AV. IKZF1 deletions
in pediatric acute lymphoblastic leukemia: still a poor
prognostic marker? Blood. 2020;135(4):252-260.
doi:10.1182/blood.2019000813
33. Feng J, Guo Y, Yang W, et al. Childhood Acute B-
Lineage Lymphoblastic Leukemia With CDKN2A/B
Deletion Is a Distinct Entity With Adverse Genetic
Features and Poor Clinical Outcomes. Front Oncol.
2022;12. doi:10.3389/fonc.2022.878098
34. Ampatzidou M, Papadhimitriou SI, Paisiou A, et al.
The Prognostic Effect of CDKN2A/2B Gene Dele-
tions in Pediatric Acute Lymphoblastic Leukemia
(ALL): Independent Prognostic Significance in BFM-
Based Protocols. Diagnostics. 2023;13(9):1589.
doi:10.3390/diagnostics13091589
35. Oshima K, Zhao J, Pérez-Durán P, et al. Mutational
and functional genetics mapping of chemotherapy
resistance mechanisms in relapsed acute lympho-
blastic leukemia. Nat Cancer. 2020;1(11):1113-1127.
doi:10.1038/s43018-020-00124-1
|
|
|
|
 |
Number 27
VOL. 27 (2), 2024 |
Number 27
VOL. 27 (1), 2024 |
Number 26
Number 26 VOL. 26(2), 2023 All in one |
Number 26
VOL. 26(2), 2023 |
Number 26
VOL. 26, 2023 Supplement |
Number 26
VOL. 26(1), 2023 |
Number 25
VOL. 25(2), 2022 |
Number 25
VOL. 25 (1), 2022 |
Number 24
VOL. 24(2), 2021 |
Number 24
VOL. 24(1), 2021 |
Number 23
VOL. 23(2), 2020 |
Number 22
VOL. 22(2), 2019 |
Number 22
VOL. 22(1), 2019 |
Number 22
VOL. 22, 2019 Supplement |
Number 21
VOL. 21(2), 2018 |
Number 21
VOL. 21 (1), 2018 |
Number 21
VOL. 21, 2018 Supplement |
Number 20
VOL. 20 (2), 2017 |
Number 20
VOL. 20 (1), 2017 |
Number 19
VOL. 19 (2), 2016 |
Number 19
VOL. 19 (1), 2016 |
Number 18
VOL. 18 (2), 2015 |
Number 18
VOL. 18 (1), 2015 |
Number 17
VOL. 17 (2), 2014 |
Number 17
VOL. 17 (1), 2014 |
Number 16
VOL. 16 (2), 2013 |
Number 16
VOL. 16 (1), 2013 |
Number 15
VOL. 15 (2), 2012 |
Number 15
VOL. 15, 2012 Supplement |
Number 15
Vol. 15 (1), 2012 |
Number 14
14 - Vol. 14 (2), 2011 |
Number 14
The 9th Balkan Congress of Medical Genetics |
Number 14
14 - Vol. 14 (1), 2011 |
Number 13
Vol. 13 (2), 2010 |
Number 13
Vol.13 (1), 2010 |
Number 12
Vol.12 (2), 2009 |
Number 12
Vol.12 (1), 2009 |
Number 11
Vol.11 (2),2008 |
Number 11
Vol.11 (1),2008 |
Number 10
Vol.10 (2), 2007 |
Number 10
10 (1),2007 |
Number 9
1&2, 2006 |
Number 9
3&4, 2006 |
Number 8
1&2, 2005 |
Number 8
3&4, 2004 |
Number 7
1&2, 2004 |
Number 6
3&4, 2003 |
Number 6
1&2, 2003 |
Number 5
3&4, 2002 |
Number 5
1&2, 2002 |
Number 4
Vol.3 (4), 2000 |
Number 4
Vol.2 (4), 1999 |
Number 4
Vol.1 (4), 1998 |
Number 4
3&4, 2001 |
Number 4
1&2, 2001 |
Number 3
Vol.3 (3), 2000 |
Number 3
Vol.2 (3), 1999 |
Number 3
Vol.1 (3), 1998 |
Number 2
Vol.3(2), 2000 |
Number 2
Vol.1 (2), 1998 |
Number 2
Vol.2 (2), 1999 |
Number 1
Vol.3 (1), 2000 |
Number 1
Vol.2 (1), 1999 |
Number 1
Vol.1 (1), 1998 |
|
|
